CLINICAL_TRIALS trial_result · 2021-02-05

Clinical Trial Update: Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) [Phase 3]

Phase 3 study of KRN23 (burosumab) in adults with X-linked hypophosphatemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Kyowa Kirin, Inc. | Conditions: X-linked Hypophosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2021-02-05